A comprehensive review of mercury provoked autism

Indian Journal of Medical Research

Volumn 128, Issue 4, 2008, Pages 383-411

  Geier, D A ^a   King, P G ^b   Sykes, L K ^b   Geier, Mark R ^c  

^a Institute of Chronic Illnesses Inc   (United States)

^b Department of Research   (United States)

^c Genetic Centers of America   (United States)

Author keywords

Autistic; Glutathione; Neurodevelopmental disorder; Testosterone

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMALGAM; ANTIANDROGEN; CHELATING AGENT; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; ENDOTOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; LEUPRORELIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MERCURY; METALLOTHIONEIN; METHIONINE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PORPHYRIN; PRASTERONE; PRASTERONE SULFATE; RHESUS D ANTIBODY; THIOMERSAL; UROPORPHYRIN; VACCINE;

ASPERGER SYNDROME; AUTISM; BLOOD BRAIN BARRIER; BLOOD LEVEL; BRAIN LEVEL; CHELATION THERAPY; CLINICAL FEATURE; CYTOTOXICITY; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DNA FRAGMENTATION; DNA SYNTHESIS; DRUG FORMULATION; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; EPIDEMIC; FETOTOXICITY; FOOD CONTAMINATION; FOOD POISONING; GENETIC SUSCEPTIBILITY; HAIR LEVEL; HUMAN; IMMUNOGENETICS; MERCURIALISM; NEUROTOXICITY; NONHUMAN; PERINATAL DRUG EXPOSURE; REVIEW; SEX DIFFERENCE; URINE LEVEL;

AUTISTIC DISORDER; ENVIRONMENTAL EXPOSURE; HUMANS; MERCURY;

EID: 61849128276     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (167)

1. Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol 2006; 36: 609-62.
2. Winship KA. Organic mercury compounds and their toxicity. Adverse Drug React Acute Poisoning Rev 1986; 5: 141-80.
3. Winship KA. Toxicity of mercury and its inorganic salts. Adverse Drug React Acute Poisoning Rev 1985; 4: 129-60.
4. Geier DA, Sykes LK, Geier MR. A review of thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness. J Toxicol Environ Health B Crit Rev 2007; 10: 575-96.
5. Centers for Disease Control and Prevention (CDC). Blood and hair mercury levels in young children and women of childbearing age - United States, 1999. MMWR Morb Mortal Wkly Rep 2001; 50: 140-3.
6. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360: 1737-41.
7. Belson MG, Schier JG, Patel MM. CDC. Case definitions for chemical poisoning. MMWR Recomm Rep 2005; 54: 1-24.
8. Stajich GV, Lopez GP, Harry SW, Sexson WR. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr 2000; 136: 679-81.
9. Marques RC, Dorea JG, Fonseca MF, Bastos WR, Malm O. Hair mercury in breast-fed infants exposed to thimerosal-preserved vaccines. Eur J Pediatr 2007; 166: 935-41.
10. Redwood L, Bernard S, Brown D. Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology 2001; 22: 691-7.
11. Bigham M, Copes R. Thiomersal in vaccines: balancing the risk of adverse effects with the risk of vaccine-preventable disease. Drug Saf 2005; 28: 89-101.
12. Geier DA, Geier MR. An assessment of downward trends in neurodevelopmental disorders in the United States following removal of thimerosal from childhood vaccines. Med Sci Monit 2006; 12: CR231-9.
13. Geier DA, Geier MR. A prospective study of thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. J Matern Fetal Neonatal Med 2007; 20: 385-90.
14. Centers for Disease Control and Prevention (CDC). Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 1999; 48: 563-5.
15. Centers for Disease Control and Prevention (CDC). Notice to readers: update on the supply of tetanus and diphtheria toxoids and of diphtheria and tetanus toxoids and acellular pertussis vaccine. MMWR Morb Mortal Wkly Rep 2001; 50: 189-90.
16. Geier DA, King PG, Geier MR. Influenza vaccine: review of effectiveness of the U.S. immunization program, and policy considerations. J Am Phys Surg 2006; 11: 69-74.
17. Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 2002; 51: 1-35.
18. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2008. MMWR Morb Mortal Wkly Rep 2007; 56: Q1-4.
19. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveill Summ 2007; 56: 12-28.
20. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network, six sites, United States, 2000. MMWR Surveill Summ 2007; 56: 1-11.
21. Nelson BK. Evidence for Behavioural teratogenicity in humans. J Appl Toxicol 1991; 11: 33-7.
22. Faustman EM, Silbernagel SM, Fenske RA, Burbacher TM, Ponce RA. Mechanisms underlying children's susceptibility to environmental toxicants. Environ Health Perspect 2000; 108 (Suppl 1): 13-21.
23. National Research Council; Committee on the Toxicological Effects of Methylmercury. Toxicological effects of methylmercury. Washington, DC: National Academy Press; 2000.
24. Mutter J, Naumann J, Guethlin C. Comments on the article "the toxicology of mercury and its chemical compounds" by Clarkson and Mago (2006). Crit Rev Toxicol 2007; 37: 537-49.
25. Mutter J, Naumann J, Schneider R, Walach H, Haley B. Mercury and autism: accelerating evidence? Neuro Endocrinol Lett 2005; 26: 439-46.
26. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning. Med Hypotheses 2001; 56: 462-71.
27. Bernard S, Enayati A, Roger H, Binstock T, Redwood L. The role of mercury in the pathogenesis of autism. Mol Psychiatry 2002; 7 (Suppl 2): S42-3.
28. McGinnis WR. Mercury and autistic gut disease. Environ Health Perspect 2001; 109: A303-4.
29. Blaxill MF, Redwood L, Bernard S. Thimerosal and autism? A plausible hypothesis that should not be dismissed. Med Hypotheses 2004; 62: 788-94.
30. Chrysochoou C, Rutishauser C, Rauber-Luthy C, Neuhaus T, Boltshauser E, Superti-Furga A. An 11-month-old boy with psychomotor regression and auto-aggressive Behaviour. Eur J Pediatr 2003; 162: 559-61.
31. Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing Thimerosal. Environ Health Perspect 2005; 113: 1015-21.
32. Suzuki T, Takemoto TL, Kashiwazaki H, Miyama T. Metabolic fate of ethylmercury salts in man and animals. In: Miller MW, Clarkson TW, editors. Mercury, mercurials, mercaptans. Springfield, IL: Charles C. Thomas; 1973. p. 209-40.
33. Aschner M, Aschner JL. Mercury neurotoxicity: mechanisms of blood-brain barrier transport. Neurosci Biobehav Rev 1990; 14: 169-76.
34. Sugita M. The biological half-time of heavy metals. The existence of a third, "slowest" component. Int Arch Occup Environ Health 1978; 41: 25-40.
35. Orct T, Blanusa M, Lazarus M, Varnai VM, Kostial K. Comparison of organic and inorganic mercury distribution in suckling rat. J Appl Toxicol 2006; 26: 536-9.
36. Minami T, Oda K, Gima N, Yamazaki H. Effects of lipopolysaccharide and chelator on mercury content in the cerebrum of thimerosal-administered mice. Environ Toxicol Phar 2007; 24: 316-20.
37. Geier DA, Geier MR. Clinical implications of endotoxin concentrations in vaccines. Ann Pharmacother 2002; 36: 776-80.
38. Geier MR, Stanbro H, Merril CR. Endotoxins in commercial vaccines. Appl Environ Microbiol 1978; 36: 445-9.
39. Geier MR, Geier DA, Zahalsky AC. Influenza vaccination and Guillain Barre syndrome. Clin Immunol 2003; 107: 116-21.
40. Charleston JS, Body RL, Bolender RP, Mottet NK, Vahter ME, Burbacher TM. Changes in the number of astrocytes and microglia in the thalamus of the monkey Macaca fascicularis following long-term subclinical methylmercury exposure. Neurotoxicology 1996; 17: 127-38.
41. Charleston JS, Body RL, Mottet NK, Vahter ME, Burbacher TM. Autometallographic determination of inorganic mercury distribution in the cortex of the calcarine sulcus of the monkey Macaca fascicularis following long-term subclinical exposure to methylmercury and mercuric chloride. Toxicol Appl Pharmacol 1995; 132: 325-33.
42. Charleston JS, Bolender RP, Mottet NK, Body RL, Vahter ME, Burbacher TM. Increases in the number of reactive glia in the visual cortex of Macaca fascicularis following subclinical long-term methyl mercury exposure. Toxicol Appl Pharmacol 1994; 129: 196-206.
43. Vahter ME, Mottet NK, Friberg LT, Lind SB, Charleston JS, Burbacher TM. Demethylation of methyl mercury in different brain sites of Macaca fascicularis monkeys during long-term subclinical methyl mercury exposure. Toxicol Appl Pharmacol 1995; 134: 273-84.
44. Vahter M, Mottet NK, Friberg L, Lind B, Shen DD, Burbacher T. Speciation of mercury in the primate blood and brain following long-term exposure to methyl mercury. Toxicol Appl Pharmacol 1994; 124: 221-9.
45. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57: 67-81.
46. Hornig M, Chian D, Lipkin WI. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol Psychiatry 2004; 9: 833-45.
47. Burke K, Chen Y, Li B, Petrov A, Joshi P, Berman RF, et al. Methylmercury elicits rapid inhibition of cell proliferation in the developing brain and decreases cell cycle regulator, cyclin E. Neurotoxicology 2006; 27: 970-81.
48. Falluel-Morel A, Sokolowski K, Sisti HM, Zhou X, Shors TJ, Dicicco-Bloom E. Developmental mercury exposure elicits acute hippocampal cell death, reductions in neurogenesis, and severe learning deficits during puberty. J Neurochem 2007; 103: 1968-81.
49. Geier DA, Geier MR. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 2006; 27: 401-13.
50. Geier DA, Geier MR. A review of the Vaccine Adverse Event Reporting System database. Expert Opin Pharmacother 2004; 5: 691-8.
51. Geier DA, Geier MR. A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit 2005; 11:CR160-70.
52. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003; 112: 1039-48.
53. Verstraeten T. Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline. Pediatrics 2004; 113: 932.
54. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 2003; 6: 97-102.
55. Geier DA, Geier MR. A comparative evaluation of the effects of MMR immunization and mercury doses from thimerosal-containing childhood vaccines on the population prevalence of autism. Med Sci Monit 2004; 10: PI33-9.
56. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003; 25: 101-6.
57. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry 2008; 65: 19-24.
58. Heron J, Golding J; ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004; 114: 577-83.
59. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics 2004; 114: 584-91.
60. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118: e139-50.
61. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290: 1763-6.
62. Marques RC, Bernardi JV, Dorea JG, Bastos WR, Malm O. Principal component analysis and discrimination of variables associated with pre- and post-natal exposure to mercury. Int J Hyg Environ Health 2008; 211: 606-14.
63. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in the first baby haircuts of autistic children. Int J Toxicol 2003; 22: 277-85.
64. Miles JH, Takahashi TN. Lack of association between Rh status, Rh immune globulin in pregnancy and autism. Am J Med Genet A 2007; 143: 1397-407.
65. Bernard S, Blaxill M, Redwood L. Re: Miles & Takahashi paper on RhIg and autism. Am J Med Genet A 2008; 146: 405-6.
66. Counter SA, Buchanan LH, Ortega F, Laurell G. Elevated blood mercury and neuro-otological observations in children of the Ecuadorian gold mines. J Toxicol Environ Health A 2002; 65: 149-63.
67. Counter SA, Buchanan LH, Ortega F. Neurocognitive screening of mercury-exposed children of Andean gold miners. Int J Occup Environ Health 2006; 12: 209-14.
68. Palmer RF, Blanchard S, Stein Z, Mandell D, Miller C. Environmental mercury release, special education rates, and autism disorder: an ecological study of Texas. Health Place 2006; 12: 203-9.
69. Rury J. Links between environmental mercury, special education, and autism in Louisiana [dissertation]. Baton Rouge (LA): Louisiana State University; 2006.
70. Windham GC, Zhang L, Gunier R, Croen LA, Grether JK. Autism spectrum disorders in relation to distribution of hazardous air pollutants in the San Francisco Bay area. Environ Health Perspect 2006; 114: 1438-44.
71. Adams JB, Romdalvik G, Levine KE, Hu LW. Mercury in firstcut baby hair of children with autism vs. typically-developing children. Environ Toxicol Chem 2008; 90: 739-53.
72. Kern JK, Grannemann BD, Trivedi MH, Adams JB. Sulfhydryl-reactive metals in autism. J Toxicol Environ Health A 2007; 70: 715-21.
73. Adams JB, Holloway CE, George F, Quig D. Analyses of toxic metals and essential minerals in the hair of Arizona children with autism and associated conditions, and their mothers. Biol Trace Elem Res 2006; 110: 193-209.
74. Williams PG, Hersh JH, Allard A, Sears LL. A controlled study of mercury levels in hair samples of children with autism as compared to their typically developing siblings. Res Autism Spectrum Disord 2008. 2: 170-5.
75. Fido A, Al-Saad S. Toxic trace elements in the hair of children with autism. Autism 2005; 9: 290-8.
76. Bradstreet J, Geier DA, Kartzinel JJ, Adams JB, Geier MR. A case-control study of mercury burden in children with autistic spectrum disorders. J Am Phys Surg 2003; 8: 76-9.
77. Geier DA, Geier MR. A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A 2007; 70: 837-51.
78. Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A 2007; 70: 1046-51.
79. Desoto MC, Hitlan RT. Blood levels of mercury are related to diagnosis of autism: a reanalysis of an important data set. J Child Neurol 2007; 22: 1308-11.
80. Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J Toxicol Environ Health A 2007; 70: 1723-30.
81. Geier DA, Geier MR. A prospective assessment of porphyrins in autistic disorders: a potential marker for heavy metal exposure. Neurotox Res 2006; 10: 57-64.
82. Nataf R, Skorupka C, Amet L, Lam A, Springbett A, Lathe R. Porphyrinuria in childhood autistic disorder: implications for environmental toxicity. Toxicol Appl Pharmacol 2006; 214: 99-108.
83. Pingree SD, Simmonds PL, Rummel KT, Woods JS. Quantitative evaluation of urinary porphyrins as a measure of kidney mercury content and mercury body burden during prolonged methylmercury exposure in rats. Toxicol Sci 2001; 61: 234-40.
84. Woods JS. Altered porphyrin metabolism as a biomarker of mercury exposure and toxicity. Can J Physiol Pharmacol 1996; 74: 210-5.
85. Woods JS, Martin MD, Naleway CA, Echeverria D. Urinary porphyrin profiles as a biomarker of mercury exposure: studies on dentists with occupational exposure to mercury vapor. J Toxicol Environ Health 1993; 40: 235-46.
86. Echeverria D, Heyer NJ, Martin MD, Naleway CA, Woods JS, Bittner AC Jr. Behavioural effects of low-level exposure to elemental Hg among dentists. Neurotoxicol Teratol 1995; 17: 161-8.
87. Boso M, Emanuele E, Minoretti P, Arra M, Politi P, Ucelli di Nemi S, et al. Alterations of circulating endogenous secretory RAGE and S100A9 levels indicating dysfunction of the AGE-RAGE axis in autism. Neurosci Lett 2006; 410: 169-73.
88. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci 2004; 75: 2539-49.
89. Ming X, Stein TP, Brimacombe M, Johnson WG, Lambert GH, Wagner GC. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 379-84.
90. Yao Y, Walsh WJ, McGinnis WR. Pratico D. Altered vascular phenotype in autism: correlation with oxidative stress. Arch Neurol 2006; 63: 1161-4.
91. Franco JL, Braga Hde C, Nunes AK, Ribas CM, Stringari J, Silva AP, et al. Lactational exposure to inorganic mercury: evidence of neurotoxic effects. Neurotoxicol Teratol 2007; 29: 360-7.
92. Kobal AB, Horvat M, Prezelj M, Briski AS, Krsnik M, Dizdarevic T, et al. The impact of long-term past exposure to elemental mercury on antioxidative capacity and lipid peroxidation in mercury miners. J Trace Elem Med Biol 2004; 17: 261-74.
93. Sanfeliu C, Sebastia J, Cristofol R, Rodriguez-Farre E. Neurotoxicity of organomercurial compounds. Neurotox Res 2003; 5: 283-305.
94. Stringari J, Nunes AK, Franco JL, Bohrer D, Garcia SC, Dafre AL, et al. Prenatal methylmercury exposure hampers glutathione antioxidant system ontogenesis and causes longlasting oxidative stress in the mouse brain. Toxicol Appl Pharmacol 2008; 227: 147-54.
95. Kostka B, Krajewska U, Rieske P. Platelet activation by mercuric compounds. Platelets 1997; 8: 413-7
96. Miyamoto K, Nakanishi H, Moriguchi S, Fukuyama N, Eto K, Wakamiya J, et al. Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity. Brain Res 2001; 901: 252-8.
97. Sajdel-Sulkowska EM, Lipinski B, Windom H, Audhya T, McGinnis W. Oxidative stress in autism: elevated cerebellar 3-nitrotyrosine levels. Am J Biochem Biotechnol 2008; 4: 73-84.
98. Evans TA, Siedlak SL, Lu L, Fu X, Wang Z, McGinnis WR, et al. The autistic phenotype exhibits a remarkably localized modification of brain protein by products of free radical-induced lipid oxidation. Am J Biochem Biotechnol 2008; 4: 61-72.
99. Lopez-Hurtado E, Prieto JJ. A microscopic study of language-related cortex in autism. Am J Biochem Biotechnol 2008; 4: 130-45.
100. Opitz H, Schweinsberg F, Grossmann T, Wendt-Gallitelli MF, Meyermann R. Demonstration of mercury in the human brain and other organs 17 years after metallic mercury exposure. Clin Neuropathol 1996; 15: 138-44.
101. Deth RC, Waly M. How genetic risks combine with thimerosal to inhibit methionine synthase and cause autism. Fall DAN! Conference; 2004 October 1-3; Los Angeles, CA: Defeat Autism Now. p. 161-74.
102. Walker SJ, Segal J, Aschner M. Cultured lymphocytes from autistic children and non-autistic siblings up-regulate heat shock protein RNA in response to thimerosal challenge. Neurotoxicology 2006; 27: 685-92.
103. Environmental Working Group. Overloaded? New science, new insights about mercury and autism in susceptible children. Washington, DC: EWG Action Fund; 2004.
104. Geier DA, Geier MR. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 2006; 66: 182-8.
105. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80: 1611-7.
106. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 947-56.
107. Suh JH, Walsh WJ, McGinnis WR, Lewis A, Ames BN. Altered sulfur amino acid metabolism in immune cells of children diagnosed with autism. Am J Biochem Biotechnol 2008; 4: 105-113.
108. Waring RH, Klovrza LV. Sulphur metabolism in autism. J Nutr Environ Med 2000; 10: 25-32.
109. James SJ. Oxidative stress and the metabolic pathology of autism. National Autism Conference; 2007 November 8-11; Atlanta, GA: National Autism Association; 2007. p. 46-55.
110. Pasca SP, Nemes B, Vlase L, Gagyi CE, Dronca E, Miu AC, et al. High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci 2006; 78: 2244-8.
111. Sogut S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, et al. Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 2003; 331: 111-7.
112. Yorbik O, Sayal A, Akay C, Akbiyik DI, Sohmen T. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 341-3.
113. Zoroglu SS, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, et al. Increased oxidative stress and altered activities of erythrocyte free radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci 2004; 254: 143-7.
114. Boris M, Goldblatt A, Galanko J, James SJ. Association of MTHFR gene variants with autism. J Am Phys Surg 2004; 9: 106-8.
115. Williams TA, Mars AE, Buyske SG, Stenroos ES, Wang R, Factura-Santiago MF, et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med 2007; 161: 356-61.
116. Buyske S, Willaims TA, Mars AE, Stenroos ES, Ming SX, Wang R, et al. Analysis of case-parent trios at a locus with a deletion allele: association of GSTM1 with autism. BMC Genet 2006; 7: 8.
117. Serajee FJ, Nabi R, Zhong H, Huq M. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol 2004; 19: 413-7.
118. Grandjean P, Weihe P, White RF, Debes F. Cognitive performance of children prenatally exposed to "safe" levels of methylmercury. Environ Res 1998; 77: 165-72.
119. Clarkson TW, Nordberg GF, Sager PR. Reproductive and developmental toxicity of metals. Scand J Work Environ Health 1985; 11: 145-54.
120. Sager PR, Aschner M, Rodier PM. Persistent, differential alterations in developing cerebellar cortex of male and female mice after methylmercury exposure. Brain Res 1984; 314: 1-11.
121. Haley BE. Mercury toxicity: genetic susceptibility and synergistic effects. Med Veritas 2005; 2: 535-42.
122. Olivieri G, Novakovic M, Savaskan E, Meier F, Baysang G, Brockhaus M, et al. The effects of beta-estradiol on SHSY5Y neuroblastoma cells during heavy metal induced oxidative stress, neurotoxicity and beta-amyloid secretion. Neuroscience 2002; 113: 849-55.
123. Oliveira FR, Ferreira JR, dos Santos CM, Macedo LE, de Oliveira RB, Rodrigues JA, et al. Estradiol reduces cumulative mercury and associated disturbances in the hypothalamus-pituitary axis of ovariectomized rats. Ecotoxicol Environ Saf 2006; 63: 488-93.
124. Thomas DJ, Fisher HL, Sumler MR, Mushak P, Hall LL. Sexual differences in the excretion of organic and inorganic mercury by methyl mercury-treated rats. Environ Res 1987; 43: 203-16.
125. Cheek DB, Hetzel BS, Hine DC. Evidence of adrenal cortical function in pink disease. Med J Aust 1951; 2: 6-8.
126. Barregard L, Lindstedt G, Schutz A, Sallsten G. Endocrine function in mercury exposed chloralkali workers. Occup Environ Med 1994; 51: 536-40.
127. Freeman HC, Sangalang GB. A study of the effects of methyl mercury, cadmium, arsenic, selenium, and a PCB, (Aroclor 1254) on adrenal and testicular steroidogeneses in vitro, by the gray seal Halichoerus grypus. Arch Environ Contam Toxicol 1977; 5: 369-83.
128. Veltman JC, Maines MD. Alterations of heme, cytochrome P-450, and steroid metabolism by mercury in rat adrenal. Arch Biochem Biophys 1986; 248: 467-78.
129. Hinfray N, Porcher JM, Brion F. Inhibition of rainbow trout ( Oncorhynchus mykiss) P450 aromatase activities in brain and ovarian microsomes by various environmental substances. Comp Biochem Physiol C Toxicol Pharmacol 2006; 144: 252-62.
130. Ryan RA, Carrol J. Studies on a 3beta-hydroxysteroid sulphotransferase from rat liver. Biochim Biophys Acta 1976; 429: 391-401.
131. Xu F, Suiko M, Sakakibara Y, Pai TG, Liu MC. Regulatory effects of divalent metal cations on human cytosolic sulfotransferases. J Biochem 2002; 132: 457-62.
132. Baron-Cohen S, Knickmeyer RC, Belmonte MK. Sex differences in the brain: implications for explaining autism. Science 2005; 310: 819-23.
133. Manning JT, Baron-Cohen S, Wheelwright S, Sanders G. The 2nd to 4th digit ratio and autism. Dev Med Child Neurol 2001; 43: 160-4.
134. de Bruin EI, Verheij F, Wiegman T, Ferdinand RF. Differences in finger length ratio between males with autism, pervasive developmental disorder-not otherwise specified, ADHD, and anxiety disorders. Dev Med Child Neurol 2006; 48: 962-5.
135. Lutchmaya S, Baron-Cohen S, Raggatt P, Knickmeyer R, Manning JT. 2nd to 4th digit ratios, fetal testosterone and estradiol. Early Hum Dev 2004; 77: 23-8.
136. Ingudomnukul E, Baron-Cohen S, Wheelwright S, Knickmeyer R. Elevated rates of testosterone-related disorders in women with autism spectrum conditions. Horm Behav 2007; 51: 597-604.
137. Knickmeyer RC, Wheelwright S, Hoekstra R, Baron-Cohen S. Age of menarche in females with autism spectrum conditions. Dev Med Child Neurol 2006; 48: 1007-8.
138. Tordjman S, Ferrari P, Sulmont V, Duyme M, Roubertoux P. Androgenic activity in autism. Am J Psychiatry 1997; 154: 1626-7.
139. Geier DA, Geier MR. A prospective assessment of androgen levels in patients with autistic spectrum disorders: biochemical underpinnings and suggested therapies. Neuro Endocrinol Lett 2007; 28: 565-73.
140. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology 2006; 13: 171-81.
141. Leong CC, Syed NI, Lorcheider FL. Retrograde degeneration of neurite membrane structural integrity of nerve growth cones following in vitro exposure to mercury. Neuroreport 2001; 12: 733-7.
142. Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, et al. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry 2004; 9: 358-70.
143. Deth R, Muratore C, Benzecry J, Power-Charnitsky VA, Waly M. How environmental and genetic factors combine to cause autism: A redox/ methylation hypothesis. Neurotoxicology 2008; 29: 190-201.
144. Parran DK, Barker A, Ehrich M. Effects of thimerosal on NGF signal transduction and cell death in neuroblastoma cells. Toxicol Sci 2005; 86: 132-40.
145. Baskin DS, Ngo H, Didenko VV. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci 2003; 74: 361-8.
146. Ariano P, Erriquez J, Gilardino A, Ferraro M, Lovisolo D, Distasi C. Calcium signals and the in vitro migration of chick ciliary ganglion cells. Cell Calcium 2006; 40: 63-71.
147. Toimela T, Tahti H. Mitochondrial viability and apoptosis induced by aluminum, mercuric mercury and methylmercury in cell lines of neural origin. Arch Toxicol 2004; 78: 565-74.
148. James SJ, Slikker W 3rd, Melnyk S, New E, Pogribna M, Jernigan S. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005; 26: 1-8.
149. Kim MS, Shigenaga J, Moser A, Grunfeld C, Feingold KR. Suppression of DHEA sulfotransferase (Sult2A1) during the acute-phase response. Am J Physiol Endocrinol Metab 2004; 287: E731-8.
150. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in "low-functioning" autistic children: a pilot study. Biol Psychiatry 1999; 46: 420-4.
151. Strous RD, Golubchik P, Maayan R, Mozes T, Tuati-Werner D, Weizman A, et al. Lowered DHEA-S plasma levels in adult individuals with autistic disorder. Eur Neuropsychopharmacol 2005; 15: 305-9.
152. Giltay EJ, Hoogeveen EK, Elbers JM, Gooren LJ, Asscheman H, Stehouwer CD. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998; 83: 550-3.
153. Giltay EJ, Verhoef P, Gooren LJ, Geleijnse JM, Schouten EG, Stehouwer CD. Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals. Atherosclerosis 2003; 168: 139-46.
154. Vrbikova J, Tallova J, Bicikova M, Dvorakova K, Hill M, Starka L. Plasma thiols and androgen levels in polycystic ovary syndrome. Clin Chem Lab Med 2003; 41: 216-21.
155. Prudova A, Albin M, Bauman Z, Lin A, Vitvitsky V, Banerjee R. Testosterone regulation of homocysteine metabolism modulates redox status in human prostate cancer cells. Antioxid Redox Signal 2007; 9: 1875-81.
156. Herbert MR, Ziegler DA, Deutsch CK, O'Brien LM, Kennedy DN, Filipek PA, et al. Brain asymmetries in autism and developmental language disorder: a nested whole-brain analysis. Brain 2005; 128: 213-26.
157. Knickmeyer RC, Baron-Cohen S. Fetal testosterone and sex differences in typical social development and in autism. J Child Neurol 2006; 21: 825-45.
158. Knickmeyer R, Baron-Cohen S, Fane BA, Wheelwright S, Mathews GA, Conway GS, et al. Androgens and autistic traits: A study of individuals with congenital adrenal hyperplasia. Horm Behav 2006; 50: 148-53.
159. Knickmeyer R, Baron-Cohen S, Raggatt P, Taylor K, Hackett G. Fetal testosterone and empathy. Horm Behav 2006; 49: 282-92.
160. Knickmeyer R, Baron-Cohen S, Raggatt P, Taylor K. Foetal testosterone, social relationships, and restricted interests in children. J Child Psychol Psychiatry 2005; 46: 198-210.
161. Radominska A, Comer KA, Zimniak P, Falany J, Iscan M, Falany CN. Human liver steroid sulphotransferase Sulphates bile acids. Biochem J 1990; 272: 597-604.
162. White JF. Intestinal pathology in autism. Exp Biol Med (Maywood) 2003; 228: 639-49.
163. Geier MR, Geier DA. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses 2005; 64: 946-54.
164. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev 2006; 9: 485-99.
165. Lonsdale D, Shamberger RJ, Audhya T. Treatment of autism spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuro Endocrinol Lett 2002; 23: 303-8.
166. Geier DA, Geier MR. A clinical trial of combined antiandrogen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol Lett 2006; 27: 833-8.
167. Patel K, Curtis LT. A comprehensive approach to treating autism and attention-deficit hyperactivity disorder: a prepilot study. J Altern Complement Med 2007; 13: 1091-8.